We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Progression-free survival as a surrogate marker of overall survival.
- Authors
Escudier, Bernard
- Abstract
The author reflects on the utilization of progression-free survival (PFS) as a surrogate marker of potency in the treatment of cancer for the patient's overall survival (OS). He cites that the use of PFS as a reproducible endpoint is feasible as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) frequently mandate an independent radiological review. He examines the use of PFS in the case of metastatic renal cell carcinoma (mRCC).
- Subjects
EDITORIALS; CANCER treatment; CANCER prognosis; HEALTH outcome assessment; RENAL cell carcinoma
- Publication
Cancer (0008543X), 2011, Vol 117, Issue 12, p2586
- ISSN
0008-543X
- Publication type
Article
- DOI
10.1002/cncr.25955